Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Congenital Athymia

Blood & Immune

Congenital Athymia Clinical Trials and Treatments

Also called thymic aplasia, congenital thymic aplasia, complete DiGeorge syndrome

Congenital athymia results from the absence or severe hypoplasia of the thymus, an organ in the upper chest where T lymphocytes mature and undergo selection. Without a functional thymus, the body cannot produce naive T cells, leaving patients profoundly immunodeficient and unable to mount adaptive immune responses against pathogens. The condition is distinct from severe combined immunodeficiency (SCID) in that the underlying defect is in the thymic microenvironment rather than in the hematopoietic stem cells themselves.

In plain words, congenital athymia means a baby is born without a working thymus, the small organ in the chest where infection-fighting T cells develop. Without these T cells, the immune system cannot fight germs well, so serious infections start in the first months of life.

Get an email when new Congenital Athymia trials open or the FDA decides. Get alerts

Congenital Athymia

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 1 study with no phase, like observational studies.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines1

Rethymic

Congenital Athymia has 1 FDA-approved medicine, 1 open or active clinical trial (1 recruiting), and no pending FDA decision.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

More about Congenital Athymia

Congenital athymia can arise from several causes. The most common is 22q11.2 deletion syndrome (DiGeorge syndrome), where deletion of a chromosomal segment disrupts pharyngeal pouch development including thymus formation. Other causes include CHARGE syndrome, mutations in FOXN1 (the nude phenotype), and maternal diabetes during pregnancy.

Keep reading about Congenital Athymia

Historically, congenital athymia was uniformly fatal within the first few years of life without bone marrow transplant, which has limited efficacy because the transplanted stem cells still lack a thymic environment for T-cell maturation.

Enzyvant's RETHYMIC (allogeneic processed thymus tissue), FDA-approved in October 2021, provides donor thymus tissue that is surgically implanted, allowing the patient's own T-cell precursors to undergo thymic education. This regenerative approach restores immune function in the majority of treated patients.

What are the symptoms of Congenital Athymia?

These are common symptoms of Congenital Athymia, and how strong they are varies from person to person.

  • Recurrent or persistent severe infections beginning in the first months of life
  • Chronic or recurrent pneumonia
  • Chronic diarrhea and gastrointestinal infections
  • Persistent oral thrush or skin yeast infections
  • Failure to thrive and difficulty gaining weight
  • Susceptibility to opportunistic infections like CMV and fungal infections

Who gets Congenital Athymia?

Present from birth. Detected through newborn SCID screening (T-cell receptor excision circles, or TRECs). Affects males and females equally. Can occur as part of 22q11.2 deletion syndrome (DiGeorge syndrome), CHARGE syndrome, FOXN1 deficiency, or diabetic embryopathy. Most patients are identified in the first year of life.

Next steps: find trials you might fitsee approved treatmentsget help payingget alerts

Which medicines are FDA-approved for Congenital Athymia?

There is currently 1 FDA-approved medication for Congenital Athymia.

allogeneic processed thymus tissue-agdc
Sumitomo Pharma America (developed by Enzyvant Therapeutics, now part of Sumitomo Pharma)
Search

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

How to get help paying for Congenital Athymia treatment

Charity funds and drugmaker programs for Congenital Athymia, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Drugmaker programs
Open a medicine for who qualifies, by insurance type.

Open the full patient assistance finder →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Congenital Athymia

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Congenital Athymia resources

Reputable organizations and medical references for learning more about Congenital Athymia, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Congenital Athymia

Use this Congenital Athymia clinical trial finder to see the 1 study recruiting patients in the United States and worldwide, with eligibility criteria in plain English. It does not test a treatment; it follows patients over time. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

1 active trial worldwide
Filter:
Sort:
RecruitingObservational study, no treatment givenRecently updatedNCT05329935

Congenital Athymia Patient Registry

Intervention: Cultured Thymus Tissue

Sponsor: Sumitomo Pharma Switzerland GmbH

This Congenital Athymia Patient Registry is an observational exposure-based registry study. It uses a prospective cohort design to follow patients who have been treated with RETHYMIC.

Ages 0 Years to 21 Years1 location
Started May 2022Updated yesterdayEst. Apr 2027 (~5 months)
Find Congenital Athymia trials near you, ranked by distance →
Active trial locations1 city in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.

Trial Pipeline

May 2022 to Apr 2029
2023
2025
2027
2029
now
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Congenital Athymia trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Congenital Athymia foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Congenital Athymia patient communities

Facebook groups, Reddit communities and YouTube channels where Congenital Athymia patients, caregivers and advocacy groups talk.

Companies developing Congenital Athymia treatments

Drugmakers that list Congenital Athymia in their rare disease portfolio, 1 in all.

Questions people ask about Congenital Athymia